Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alkermes, Inc.
Alliance forged to develop inhaled parathyroid hormone for the treatment of osteoporosis
February 5th, 2006
Alkermes, Inc., (ALKS) and Eli Lilly and Company (LLY) announced that they have signed an agreement to develop and commercialize inhaled formulations of parathyroid hormone (PTH). The development program will utilize the Alkermes AIR pulmonary drug delivery system. Lilly's recombinant PTH, Forteo (teriparatide (rDNA origin) injection), was approved in 2002 by the Food and Drug Administration (FDA) for the treatment of osteoporosis in postmenopausal women who are at high risk for bone fracture and to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. The agreement was signed after completing extensive feasibility...
Source: Women's Health Law Weekly (2006-02-05)
|
